Description
Product Characteristics:
Aliases: c Ki ras2 antibody, c Kirsten ras protein antibody, c-K-ras antibody, c-Ki-ras antibody, Cellular c Ki ras2 proto oncogene antibody, Cellular transforming proto oncogene antibody, CFC2 antibody, cK Ras antibody, GTPase KRas antibody, K RAS p21 protein antibody, K RAS2A antibody, K RAS2B antibody, K RAS4A antibody, K RAS4B antibody, K-Ras 2 antibody, KI RAS antibody, Ki-Ras antibody, KIRSTEN MURINE SARCOMA VIRUS 2 antibody, Kirsten rat sarcoma 2 viral (v Ki ras2) oncogene homolog antibody, Kirsten rat sarcoma viral oncogene homolog antibody, KRAS antibody, KRAS proto oncogene, GTPase antibody, KRAS1 antibody, KRAS2 antibody, N-terminally processed antibody, NS antibody, NS3 antibody, Oncogene KRAS2 antibody, p21ras antibody, PR310 c K ras oncogene antibody, PR310 cK ras oncogene antibody, RALD antibody, RASK_HUMAN antibody, RASK2 antibody, Transforming protein p21 antibody, v Ki ras2 Kirsten rat sarcoma 2 viral oncogene homolog antibody, v Ki ras2 Kirsten rat sarcoma viral oncogene homolog antibody
Target Information: This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]